News Column

Investigators at Harvard University Detail Findings in Lymphoma Gene Therapy

February 3, 2014

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Data detailed on Biotechnology have been presented. According to news originating from Cambridge, Massachusetts, by NewsRx correspondents, research stated, "Thymectomy is often performed on the basis of computed tomography scan findings that are suspicious for thymoma. However, the final diagnosis may be a condition such as thymic hyperplasia or lymphoma for which thymectomy is not therapeutic."

Our news journalists obtained a quote from the research from Harvard University, "The present analysis was undertaken to determine the prevalence of a 'nontherapeutic' thymectomy. The Nationwide Inpatient Sample from 2000 through 2009 was queried to identify patients who underwent a thymectomy. Only adult patients who underwent a total thymectomy without other associated procedures were analyzed. Patients with a diagnosis of myasthenia were excluded. A nontherapeutic thymectomy was defined as a patient who underwent thymectomy with an International Classification of Diseases, Ninth Revision diagnosis code of lymphoma, thymic hyperplasia, thymic cyst, or other benign diseases of the thymus. A total of 1,306 patients were identified. Overall, 72.2% (n = 943) of thymectomies were therapeutic and 27.8% (n = 363) were nontherapeutic. The most common diagnosis in the nontherapeutic group was thymic hyperplasia (n = 174). Mortality (0.32% versus 0%; p = 0.083) and overall complication rates (25% versus 17%; p< 0.001) were higher in the therapeutic group. Patients in the nontherapeutic group were younger (median age, 41 versus 56 years; p< 0.001) and more likely to undergo a video-assisted thoracoscopic surgery thymectomy (28% versus 19%; p = 0.085). In this study, 27.8% of thymectomies were nontherapeutic, and most patients underwent an open approach. The most common benign diagnosis was thymic hyperplasia, a condition for which magnetic resonance imaging has a high predictive value."

According to the news editors, the research concluded: "Consequently, further studies are warranted to determine the optimal evaluation of patients undergoing thymectomy for presumed thymoma."

For more information on this research see: What is the Prevalence of a "Nontherapeutic" Thymectomy? Annals of Thoracic Surgery, 2014;97(1):276-282. Annals of Thoracic Surgery can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier -; Annals of Thoracic Surgery -

The news correspondents report that additional information may be obtained from M.S. Kent, Harvard University, Dept. of Econ, Cambridge, MA 02138, United States. Additional authors for this research include T. Wang, S.P. Gangadharan and R.I. Whyte (see also Biotechnology).

Keywords for this news article include: Biotechnology, Cambridge, Hyperplasia, Massachusetts, United States, Lymphoma Gene Therapy, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Cancer Gene Therapy Week

Story Tools